Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL997507 | 0.88 | P2RX3 (0.60) | P2RX3 | |
| SCHEMBL996761 | 0.86 | P2RX3 (0.62) | P2RX3 | |
| SCHEMBL2853594 | 0.83 | P2RX3 (0.53) | P2RX3 | |
| SCHEMBL997285 | 0.83 | P2RX3 (0.59) | P2RX3 | |
| SCHEMBL2849692 | 0.81 | GRIN2D (0.52) | P2RX3 | |
| SCHEMBL1046238 | 0.78 | P2RX3 (0.61) | P2RX3 | |
| SCHEMBL997350 | 0.77 | P2RX3 (1.00) | P2RX3 | |
| SCHEMBL4346635 | 0.77 | P2RX3 (0.63) | P2RX3 | |
| SCHEMBL997348 | 0.77 | P2RX3 (1.00) | P2RX3 | |
| SCHEMBL12926945 | 0.76 | P2RX3 (0.49) | P2RX3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136639-B1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2016-03-09 | — | — | EP | disclosed |
| EP-2136639-B1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-8653091-B2 | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653091-B2 | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653091-B2 | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20110009432-A1 | PYRID-2YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009432-A1 | PYRID-2YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009432-A1 | PYRID-2YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2136639-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008123963-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008123963-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009432-A1 | PYRID-2YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | IL1B, C5, HTR2C | P2RX3 82/4885CNR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.